Non-sexuality

Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Retrieved on: 
Wednesday, March 24, 2021
Human sexuality, Psychiatric diagnosis, Non-sexuality, Sexual arousal, Sexual health, Sexuality, Hypoactive sexual desire disorder, Female sexual arousal disorder, Sildenafil, Sexual desire, Asexuality, Flibanserin

The Phase 2b RESPOND study will evaluate Sildenafil Cream compared to placebo cream in pre- and peri-menopausal women over 12 weeks of at-home use following both a non-drug and placebo run-in period.

Key Points: 
  • The Phase 2b RESPOND study will evaluate Sildenafil Cream compared to placebo cream in pre- and peri-menopausal women over 12 weeks of at-home use following both a non-drug and placebo run-in period.
  • We are honored to commence the Phase 2b study of Sildenafil Cream.
  • FSAD is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire.
  • The findings of that study helped facilitate alignment with the FDA on acceptable efficacy endpoints for the Phase 2b RESPOND study and future Phase 3 program.

Global Erectile Dysfunction Drugs Market Report 2020: Forecasts to 2023, 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021
Health, Pharmaceutical, Human sexuality, Penile erection, Penis, Men's Health, Psychiatric diagnosis, Human penis, Erectile dysfunction, Non-sexuality, Sexual dysfunction

The "Drugs For Erectile Dysfunction Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drugs For Erectile Dysfunction Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
  • The erectile dysfunction (ED) drugs market consists of sales of erectile dysfunction (ED) drugs and related services.
  • Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drugs market.
  • Global Drugs For Erectile Dysfunction Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Europe Erectile Dysfunction Market & Competitive Landscape - 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 29, 2020
MEN, General Health, Health, Consumer, Human sexuality, Psychiatric diagnosis, Medical specialties, Human reproduction, Erectile dysfunction, Men's Health, Non-sexuality, Penile erection, Sildenafil, Sexual dysfunction

The "Europe Erectile Dysfunction Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Erectile Dysfunction Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report Europe Erectile Dysfunction Market and Competitive Landscape - 2020, provides comprehensive insights into the Erectile Dysfunction pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following: Erectile Dysfunction treatment options, Erectile Dysfunction late stage clinical trials pipeline, Erectile Dysfunction prevalence by countries, Erectile Dysfunction market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Erectile Dysfunction pipeline: Find out drugs in clinical trials for the treatment of Erectile Dysfunction by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Erectile Dysfunction drugs: Identify key drugs marketed and prescribed for Erectile Dysfunction in the US, including trade name, molecule name, and company
    Erectile Dysfunction market valuations: Find out the market size for Erectile Dysfunction drugs in 2019 by countries.

Global Erectile Dysfunction Market Insights, 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 17, 2020
Health, Pharmaceutical, Human sexuality, Psychiatric diagnosis, Penis, Penile erection, Human penis, Erectile dysfunction, Men's Health, Non-sexuality, Sexual dysfunction, Sildenafil

The "Global Erectile Dysfunction Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Erectile Dysfunction Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This research report provides comprehensive insights into the Erectile Dysfunction pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The report covers the following: Erectile Dysfunction treatment options, Erectile Dysfunction late stage clinical trials pipeline, Erectile Dysfunction prevalence by countries, Erectile Dysfunction market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Erectile Dysfunction pipeline: Find out drugs in clinical trials for the treatment of Erectile Dysfunction by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Erectile Dysfunction drugs: Identify key drugs marketed and prescribed for Erectile Dysfunction in the US, including trade name, molecule name, and company
    Erectile Dysfunction market valuations: Find out the market size for Erectile Dysfunction drugs in 2019 by countries.

Global Hypoactive Sexual Desire Disorder Treatment Market to Grow with a CAGR of 5.2% During the Forecast Period, 2019-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 10, 2019
Health, General Health, Human sexuality, Psychiatric diagnosis, Non-sexuality, Asexuality, Hypoactive sexual desire disorder, Sexuality, Sexual desire, HSD

The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Key Points: 
  • The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.
  • Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self-confidence and less connected with their partners.
  • Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy.
  • North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%.

Hypoactive Sexual Desire Disorder (HSDD): 2019 Pipeline Insight Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 16, 2019
Health, Pharmaceutical, Human sexuality, Non-sexuality, Asexuality, Psychiatric diagnosis, Sexuality, Hypoactive sexual desire disorder, Sexual desire, HSD

The "Hypoactive Sexual Desire Disorder (HSDD) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypoactive Sexual Desire Disorder (HSDD) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Hypoactive Sexual Desire Disorder (HSDD) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Hypoactive Sexual Desire Disorder pipeline landscape is provided which includes the disease overview and Hypoactive Sexual Desire Disorder treatment guidelines.
  • The assessment part of the report embraces, in depth Hypoactive Sexual Desire Disorder commercial assessment and clinical assessment of the pipeline products under development.

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market to 2027: Affordable Reimbursement Scenario for Pharmacotherapy Employed in the Treatment of HSDD

Retrieved on: 
Monday, September 9, 2019
Human sexuality, Non-sexuality, Asexuality, Psychiatric diagnosis, Hypoactive sexual desire disorder, Sexuality, Sexual desire, HSD, Flibanserin

The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Key Points: 
  • The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.
  • Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy.
  • North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%.
  • Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD).

Global Drugs for Erectile Dysfunction Market Will Grow to $5.18 Billion By 2022 a Report by The Business Research Company

Retrieved on: 
Friday, September 6, 2019
Penis, Human sexuality, Psychiatric diagnosis, Human penis, Penile erection, Men's Health, Erectile dysfunction, Non-sexuality, Ro, Sexual dysfunction, Venous leak

Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drugs market.

Key Points: 
  • Prevalence of chronic diseases increases the chances of erectile dysfunction among men, thereby driving the erectile dysfunction drugs market.
  • Read More On The Business Research Company's Drugs For Erectile Dysfunction Market Report:
    Patients suffering from erectile dysfunction do not seek treatment owing to factors such as lack of education, lack of awareness, strong religious beliefs, social taboo, and low socioeconomic status.
  • These benefits from drug delivery techniques will increase the scope of the erectile dysfunction drugs market.
  • The erectile dysfunction drugs market consists of sales of erectile dysfunction (ED) drugs and related services.

Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Forecasts to 2027 - Recent Approval of Vyleesi & Strong Product Pipeline Will Propel Market Growth

Retrieved on: 
Thursday, September 5, 2019
Human sexuality, Non-sexuality, Psychiatric diagnosis, Asexuality, Hypoactive sexual desire disorder, Sexuality, Sexual desire, HSD

The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Key Points: 
  • The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.
  • Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self-confidence and less connected with their partners.
  • The recent approval of Vyleesi will provide essential momentum for the HSDD market growth.
  • North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%.

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Report, 2017-2019 & 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 5, 2019
Health, Pharmaceutical, Human sexuality, Psychiatric diagnosis, Non-sexuality, Asexuality, Hypoactive sexual desire disorder, Sexuality, Sexual desire, HSD

The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Key Points: 
  • The global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.
  • Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self-confidence and less connected with their partners.
  • Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy.
  • North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%.